Skip to main content
. 2018 Mar 5;39(5):2101–2113. doi: 10.3892/or.2018.6296

Table VII.

Expression of lncRNAs related to clinical features according to the clinicopathological characteristics of patients.

UCA1 expression HULC expression


Characteristics No. High group Low group P-value High group Low group P-value
Age (years)
  <50 18   5 13 0.024   5 13 0.024
  >50 42 25 17 25 17
Sex
  Female 32 17 15 0.605 12 20 0.038
  Male 28 13 15 18 10
Lymphatic metastasis
  No 36 14 22 0.035 15 21 0.113
  Yes 24 16   8 15   9
Tumor stage
  Stage I, II 33 12 21 0.020 15 18 0.436
  Stage III, IV 27 18   9 15 12
TNM staging system
  T1+T2 32 17 15 0.605 14 18 0.301
  T3+T4 28 13 15 16 12

CHL1-AS2 expression LINC00484 expression


Characteristics No. High group Low group P-value High group Low group P-value
Age (years)
  <50 18   8 10 0.573   9   9 1.000
  >50 42 22 20 21 21
Sex
  Female 32 20 12 0.038 21 11 0.009
  Male 28 10 18   9 19
Lymphatic metastasis
  No 36 17 19 0.598 19 17 0.598
  Yes 24 13 11 11 13
Tumor stage
  Stage I, II 33 16 17 0.796 18 15 0.436
  Stage III, IV 27 14 13 12 15
TNM staging system
  T1+T2 32 13 19 0.120 20 12 0.038
  T3+T4 28 17 11 10 18

CLDN10-AS1 expression DLX6-AS1 expression


Characteristics No. High group Low group P-value High group Low group P-value
Age (years)
  <50 18   8 10 0.573   7 11 0.260
  >50 42 22 20 23 19
Sex
  Female 32 16 16 1.000 15 17 0.605
  Male 28 14 14 15 13
Lymphatic metastasis
  No 36 21 15 0.113 20 16 0.292
  Yes 24   9 15 10 14
Tumor stage
  Stage I, II 33 21 12 0.020 11 22 0.004
  Stage III, IV 27   9 18 19   8
TNM staging system
  T1+T2 32 18 14 0.301 15 17 0.605
  T3+T4 28 12 16 15 13
ADAMTS9-AS1 expression

Characteristics No. High group Low group P-value
Age (years)
  <50 18   6 12 0.091
  >50 42 24 18
Sex
  Female 32 17 15 0.605
  Male 28 13 15
Lymphatic metastasis
  No 36 20 16 0.291
  Yes 24 10 14
Tumor stage
  Stage I, II 33 18 15 0.436
  Stage III, IV 27 12 15
TNM staging system
  T1+T2 32 21 11 0.010
  T3+T4 28   9 19

lncRNAs, long non-coding RNAs.